Drug Profile
EC 234/OC 229
Alternative Names: EC-234/OC-229; Neutrolide; OC-229/EC-234Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Biomedica Management Corporation
- Class Anti-ischaemics; Small molecules
- Mechanism of Action Selectin inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Reperfusion injury
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Reperfusion injury in USA (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Reperfusion-injury in USA